What is the recommended initial dose of sparsentane?

Sparsentan is an oral prescription medication indicated to slow the decline in kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for worsening of the condition. Spaxentan is a dual endothelin angiotensin receptor antagonist (DEARA) that works by targeting two pathways involved in the progression of IgAN (endothelin-1 and angiotensin II).

Based on publicly available information, the recommended starting dose of sparsentane is200 mg, which is the standard starting dose for oral administration once daily. Patients should take the entire tablet with water before breakfast or dinner under the guidance of a doctor. The setting of this initial dose is based on a comprehensive consideration of multiple factors such as the pharmacodynamic properties of the drug, patient tolerance, and clinical trial data.

It is worth mentioning that sparsentine dosage is not set in stone. Physicians may consider increasing the dose to 400 mg, also once daily, 14 days after initial treatment if tolerated by the patient. Such dosage adjustments are intended to ensure optimal therapeutic effects of the drug in the patient's body. However, dose escalation is not a given and should be based on the patient's specific response and tolerability.

In addition, if a patient misses a dose during medication, they should take the next dose at the prescribed time rather than trying to double the dose or exceed the recommended dose. This is crucial because overdose may increase the risk of adverse effects.

In general, the recommended initial dose of sparsentane is 200 mg orally once daily and should be adjusted under the guidance of a physician. The drug's dosing and titration strategies are designed to ensure patients can receive treatment safely and effectively, thereby maximizing its potential in the treatment of primary immunoglobulin A nephropathy.

xa0

Reference link: https://www.drugs.com/filspari.html